Kailera Therapeutics priced an upsized IPO raising $625 million, positioning the offering as a record-setting debut for U.S. biotech. The company plans to use the proceeds to fund global clinical work across its obesity pipeline, led by ribupatide (KAI-9531), a once-weekly injectable GLP-1/GIP dual agonist peptide in Phase III. The IPO also included upside from underwriters’ option exercise, with total gross proceeds potentially approaching $719 million. Kailera’s obesity-first strategy is described as supported by prior funding rounds, including a Series A and a subsequent Series B, and by license origins from China-linked assets. The company’s valuation conversation matters for peers because it comes amid competition for obesity investors and shifting expectations around what targets can deliver beyond GLP-1 dominance. For biotech markets, a record IPO can also influence how quickly other sponsors move from earlier-phase candidates to larger late-stage trials. In parallel reporting, industry coverage framed Kailera as pushing for a U.S. biotech record with a clinical-stage manufacturing and development plan designed to move quickly toward registrational evidence.